Parkinson’s Disease | Disease Landscape and Forecast | G7 | 2021

Since 2015, the genericized Parkinson’s disease (PD) market has witnessed the launch of nearly a dozen unique brands (e.g., Inbrija, Kynmobi, Nourianz), and several more are on the horizon, including AbbVie’s ABBV-951, Amneal’s IPX203, and Cerevel’s tavapadon. As developers seek to carve out a clinical role for each of these products, they will introduce additional complexity to an already complicated treatment algorithm. New brands have the potential to meaningfully increase the market value, but intensifying competition, coupled with patient and payer cost-sensitivity in a crowded and mostly generic market, creates a challenging launch environment. A deep understanding of current and future market dynamics in PD will be critical for new and established players vying for a share of this increasingly competitive landscape.

Questions Answered:

  • What will be the clinical and commercial impact of emerging levodopa reformulations? Will they experience rapid uptake and alter the PD treatment paradigm, or will access hurdles and/or physician resistance limit their use?
  • How will neurologists differentiate between current and emerging adjunctive therapies for motor fluctuations and dyskinesia, and which will enjoy the greatest success in this highly generic market?
  • How will neurologists adopt the new acute rescue therapies for “off” periods, and what unmet needs remain for other novel therapies targeting motor symptoms in PD?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 25 country-specific interviews with thought-leading neurologists; supported by survey data collected for this and other Clarivate research.

Epidemiology: Total, diagnosed, and drug-treated prevalent cases of PD by country.

Emerging therapies: Phase II: 21 drugs; Phase III: 6 drugs; preregistration: 1 drug.

Market forecast features: Ten-year, annualized, drug-level sales and patient shares of key PD therapies through 2030, segmented by brands / generics.

Key companies: AbbVie, Acadia Pharmaceuticals, Acorda Therapeutics, Adamas Pharmaceuticals, Addex Therapeutics, Amneal Pharmaceuticals, Cerevel Therapeutics, Eisai, Hisamitsu Pharmaceutical, Kyowa Kirin, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Newron Pharmaceuticals, NeuroDerm, Osmotica Pharmaceuticals, Pharma Two B, Sumitomo Dainippon Pharma, Sunovion, Takeda, Teva, Theravance Biopharma, UCB, US WorldMeds, Zambon Pharma.

Key drugs: levodopa, amantadine, ampreloxetine, apomorphine, ABBV-951, AP-CD/LD, Duodopa / Duopa, dipraglurant, entacapone, Gocovri, Haruropi Tape, Inbrija, IPX203, Kynmobi, Lecigon, ND0612, Neupro, Nourianz, Nuplazid, Ongentys, Osmolex ER, pramipexole, P2B001, rasagiline, ropinirole, Rytary, selegiline, tavapadon, Trerief, Xadago.

Solution Enhancement

Disease Landscape & Forecast will feature continuous updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.